Matthew Clark, Ph.D.
President and Chief Scientific Officer, X-Chem
Matt is a world-recognized innovator and leader in the DNA-encoded library (DEL) field. He was part of X-Chem’s founding team and served as VP of chemistry and SVP of research prior to his appointment to the President and Chief Scientific Officer position. Under his scientific leadership, the company developed from a niche chemical discovery platform to a world-leading drug discovery engine serving the biopharma industry. Before joining X-Chem, Matt was director of chemistry at GlaxoSmithKline, where he led the group responsible for design and synthesis of early-iteration DELs. He began his professional career at Praecis Pharmaceuticals, where he played a key role in the early development and implementation of technologies that would become the basis for DEL. Matt is a thought leader in the DEL space, with numerous patents and key DEL publications to his name. He received his B.S. in biochemistry from the University of California, San Diego, a Ph.D. in chemistry from Cornell University, and conducted postdoctoral studies at the Massachusetts Institute of Technology. For more information, visit X-ChemRX.com.
Talk to Matt about these topics and more:
- New research and advances for DNA-encoded libraries (DELs)
- Small molecule successes founded through DEL screening
- The power of DEL to tackle challenges across industries and multiple targets
- Covalent discovery challenges and opportunities
- De-risking small molecule drug discovery
Ready to Connect?
Would you like to invite a health science expert to participate in your next piece, program, panel, or partnership? Our team is standing by to help connect you to the right source and topic:
About X-Chem
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. Visit X-ChemRX.com.
Save this page as a PDF
